P. Zannikos

发表

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

M. von Mehren, M. Mehren, E. Bayever, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Mechanism‐based Pharmacokinetic/Pharmacodynamic Meta‐analysis of Trabectedin (ET‐743, Yondelis) Induced Neutropenia

J. Pérez-Ruixo, A. Soto-Matos, P. Zannikos, 2008, Clinical pharmacology and therapeutics.

Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743, Yondelis®) in Cancer Patients

J. Pérez-Ruixo, E. Ludwig, A. Soto-Matos, 2007, Clinical pharmacokinetics.

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

J. Pérez-Ruixo, A. Soto-Matos, M. Izquierdo, 2008, Cancer Chemotherapy and Pharmacology.

Lack of Correlation between In Vitro Inhibition of CYP3A‐Mediated Metabolism by a PPAR‐γ Agonist and Its Effect on the Clinical Pharmacokinetics of Midazolam, an In Vivo Probe of CYP3A Activity

Y. Luo, J. Stevens, P. Zannikos, 2001, Journal of clinical pharmacology.

Carisbamate (RWJ-333369)

P. Zannikos, G. Novak, M. Kelley, 2011, Neurotherapeutics.

AMP 579, a Novel Adenosine Agonist for the Treatment of Acute Myocardial Infarction

K. Clark, B. Boutouyrie, P. Zannikos, 2006 .

Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End‐Stage Renal Insufficiency

S. Waldman, H. Greenberg, B. Boutouyrie, 2000, Journal of clinical pharmacology.

Cognitive effects of carisbamate in randomized, placebo-controlled, healthy-volunteer, multidose studies

K. Meador, F. Wiegand, H. Brashear, 2011, Epilepsy & Behavior.

Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate

H. Brashear, A. Greenspan, T. Verhaeghe, 2012, Journal of clinical pharmacology.

Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

L. Dirix, G. Manikhas, T. Parekh, 2011, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic‐Pharmacodynamic Modeling of the Antilipolytic Effects of an Adenosine Receptor Agonist in Healthy Volunteers

B. Jensen, S. Rohatagi, P. Zannikos, 2001, Journal of clinical pharmacology.

Prediction of Drug–Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model

L. D. De Zwart, J. Snoeys, G. Mannens, 2022, Clinical Pharmacokinetics.

Effect of nutritional obesity on the induction of CYP2B enzymes following phenobarbital treatment.

R. Blouin, L. Robertson, P. Zannikos, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Expression of the CYP3A and CYP2C11 enzymes in a nutritionally obese rodent model: response to phenobarbital treatment.

R. Blouin, L. Robertson, P. Zannikos, 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

R. Neuwirth, S. Lonial, K. Venkatakrishnan, 2010, Cancer Chemotherapy and Pharmacology.

Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group

R. Arceci, P. Adamson, F. Balis, 2011, Pediatric blood & cancer.

Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease

Yang Zhang, T. Post, J. Lippert, 2022, CPT: pharmacometrics & systems pharmacology.

Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study

B. McCrindle, L. Lesko, A. Michelson, 2021, Journal of clinical pharmacology.

Validation and application of an LC-MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma.

Hao Wang, Naidong Weng, Hao Wang, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Prediction of Drug–Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model

L. D. De Zwart, J. Snoeys, G. Mannens, 2022, Clinical Pharmacokinetics.

Pharmacokinetics and Tolerability of Rabeprazole in Children 1 to 11 Years Old With Gastroesophageal Reflux Disease

A. Mulberg, G. Leitz, P. Zannikos, 2011, Journal of pediatric gastroenterology and nutrition.

The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine.

S. Yasuda, R. Woosley, I. Wainer, 2002, British journal of clinical pharmacology.

The effect of fluconazole on the clinical pharmacokinetics of methadone

P. Zannikos, P. Rainey, L. S. Brown, 1998, Clinical pharmacology and therapeutics.

Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients.

J. Pérez-Ruixo, P. De Porre, P. Zannikos, 2006, British journal of clinical pharmacology.

Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly

R. Levy, I. Ragueneau-Majlessi, P. Zannikos, 2008, Epilepsy Research.

Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib

J. Pérez-Ruixo, V. Piotrovsky, V. Ozdemir, 2006, Cancer Chemotherapy and Pharmacology.

Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach

P. Nandy, Liping Zhang, P. Zannikos, 2017, Clinical Drug Investigation.

Effect of Carisbamate on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Participants

A. Dibernardo, H. Brashear, P. Zannikos, 2012, Journal of clinical pharmacology.

Pharmacokinetics of carisbamate (RWJ‐333369) in healthy Japanese and Western subjects

M. Bialer, T. Verhaeghe, P. Zannikos, 2009, Epilepsia.

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

D. Ettinger, A. Jimeno, M. Hidalgo, 2008, Cancer Chemotherapy and Pharmacology.

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.

R. Arceci, F. Balis, B. Widemann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytochrome P450 2B enzyme induction defect after 2,2',4,4',5,5'-hexachlorobiphenyl treatment in the fa/fa Zucker rat.

R. Blouin, L. Robertson, P. Zannikos, 1994, The Journal of pharmacology and experimental therapeutics.

Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression

W. Drevets, J. Pérez-Ruixo, Jaskaran Singh, 2020, Clinical Pharmacokinetics.

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study

W. Drevets, J. V. van Gerven, Jaskaran Singh, 2016, Psychopharmacology.

Spectrophotometric Prediction of the Dissolution Rate of Carbamazepine Tablets

Robert A. Lodder, James K. Drennen, J. Drennen, 1991, Pharmaceutical Research.

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).

S. Lonial, H. Burris, D. Reece, 2006 .

Free and total serum digoxin concentrations in a renal failure patient after treatment with digoxin immune Fab.

M. Harrison, M. Chandler, P. Zannikos, 1989, Clinical pharmacy.

Fatty Acid Amide Hydrolase Inhibition by JNJ‐42165279: A Multiple‐Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers

G. Bormans, K. Van Laere, D. Pemberton, 2018, Clinical and translational science.

Pharmacokinetics and Concentration‐Effect Analysis of Intravenous RGD891, a Platelet GPIIb/IIIa Antagonist, Using Mixed‐Effects Modeling (NONMEM)

B. Jensen, G. Rhodes, S. Rohatagi, 2000, Journal of clinical pharmacology.

Pharmacokinetics, Pharmacodynamics, and Safety of a Platelet GPIIb/IIIa Antagonist, RGD891, following Intravenous Administration in Healthy Male Volunteers

B. Jensen, S. Rohatagi, P. Zannikos, 2000, Journal of clinical pharmacology.

142 Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients with Treatment-resistant Depression

W. Drevets, A. Dibernardo, A. Krystal, 2020, CNS Spectrums.

P.327 Withdrawal symptom assessment in an esketamine safety study in patients with treatment-resistant depression

W. Drevets, A. Dibernardo, A. Krystal, 2019, European Neuropsychopharmacology.

A phase I trial and pharmacokinetic study of a 24‐hour infusion of trabectedin (Yondelis®, ET‐743) in children and adolescents with relapsed or refractory solid tumors

E. Bayever, F. Balis, B. Widemann, 2012, Pediatric blood & cancer.

First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18

R. Rosenburg, Liping Zhang, J. Goldberg, 2019, Journal of pain research.

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer

L. Weiner, J. Gallo, R. Alpaugh, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of Tipifarnib After Oral and Intravenous Administration in Subjects With Advanced Cancer

M. Piccart-Gebhart, L. Dirix, Peter M. Porre, 2006, Journal of clinical pharmacology.

Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.

J. Smit, P. Zannikos, M. Etropolski, 2013, Journal of opioid management.

Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment

J. Hohlfeld, Jaskaran Singh, M. De Meulder, 2023, Clinical Pharmacokinetics.

Pharmacokinetics, Safety, and Tolerability of Single Intravenous Infusions of an Adenosine Agonist, AMP 579, in Healthy Male Volunteers

B. Boutouyrie, B. Jensen, P. Zannikos, 1999, Journal of clinical pharmacology.

JNJ-10450232 (NTM-006), A novel non-opioid with structural similarities to acetaminophen, produces relatively long-lasting analgesia after a single dose in patients undergoing 3rd molar extraction.

E. Kuffner, C. M. Flores, C. Gelotte, 2023, Regulatory toxicology and pharmacology : RTP.

Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group

R. Arceci, P. Adamson, F. Balis, 2011, Pediatric blood & cancer.